Explore every episode of the podcast PharmaTalkRadio

This podcast features a fireside chat between Dr Ira Mellman, PICI and Dr Axel Hoos, Former CEO, Scorpion Therapeutics from the 2026 Immuno-Oncology 360° conference. Drawing on Dr Mellman’s extensive experience and current work at the Parker Institute for Cancer Immunotherapy, this conversation provides:

• Insight into the scientific and clinical trajectory of immuno-oncology
• Perspectives on the evolving role of collaboration and innovative partnership models like PICI
• Discussion of the key opportunities and challenges shaping IO innovation at scale
• A visionary outlook on what the next chapter of immuno-oncology could look like

To learn more about the IO360° Summit, please visit https://www.io360summit.com/

As alternative funding pathways decrease and fewer research grants are administered, the relationship between biotech and academia must shift in order to continue to achieve innovation and development. In this podcast, featuring a panel discussion from the 2026 Chief Medical Officer Summit 360°, CMOs and academics present on these shifts in the global clinical development ecosystem, and how academia and biotech can better partner to develop new therapies for patients, with specific examples.

To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com.

This podcast feature a panel discussion from the 2026 Chief Medical Officer Summit 360°, biotech CMOs and executives from CROs and consultancies. Together they discuss how small biotechs can accelerate clinical development with fit-for-purpose global clinical trial strategies. Specifically: 

• The benefits and challenges of running clinical trials in different regions
• When and at which phases to run clinical trials in different countries
• Bridging data for approval applications
• Managing global clinical trials in areas with different cultures and health systems

To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com.

This podcast features a panel discussion from the 2026 Chief Medical Officer Summit 360°, with biotech CMOs and representatives from pharma companies. Together, they address how interactions around partnerships or acquisitions differ from those of investment from biotech companies and how CMOs can support those conversations. This includes:

• How pharma companies analyze potential partners
• What biotech companies can do to best partner with pharma 
• How the CMO fits into various phases of transactions
• Appreciating how different c-suite colleagues and direct reports experience these transactions
• The different pharma teams CMOs will interact with
• Common challenges to partnerships and how to pre-empt them
• What happens after the acquisition

To learn more about the Chief Medical Officer Summit 360°, please visit CMOSummit360.com.

In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help sponsors avoid protocol amendments and delays.  
More specifically, Mike discusses:  

• How Advarra is leveraging past IRB data sources to identify common causes of site burden, study delays and amendments 
• What questions sponsors should be asking of AI vendors, to pick the correct partner 
• How sponsors have responded to the insights surfaced by this technology  
• Why sponsors must adapt to a flexibility mindset in order to truly make changes with downstream impact 

Tapping into research-naïve sites offers a strategic opportunity to expand patient access. That’s exactly what Endo did when faced with challenges activating sites for their orthopedic study. This case study shares how Endo enabled a new site through hands-on mentorship, infrastructure support, and trust-building— resulting in sustainable partnerships and broader patient reach.

• How naïve sites can help address access and enrollment bottlenecks
• How to support inexperienced sites with the right sponsor-led infrastructure
• What it takes to shift internal expectations and foster lasting site partnerships

Speakers:
Carrie Lewis Executive Director, Clinical Program Optimization, Endo
Suzy Montayne Site Relationship Manager, Endo
Terry Oehler, DPM Founder & CEO, Colorado Clinical Research

AstraZeneca’s US Site Engagement Leads will share how they are reimagining sponsor-site relationships through a trust-first, high-engagement operating model that emphasizes flexibility, responsiveness, and co-creation. This session will showcase how their embedded approach to collaboration has enabled faster site activation, stronger recruitment performance, and improved data delivery—backed by real metrics and lessons learned from a three-year initiative. Key topics include:

• How continuous site feedback loops and flexibility with SOPs improved startup timelines
• Metrics from a recent study showing impact: 30% faster budget negotiations, 27% reduced activation times, 68% of recruitment from 42% of sites
• Tools and tactics used to build consistency, transparency, and trust across studies
• Lessons learned and how the program has scaled globally

Speakers:
Shannon Edwards Site Engagement Lead, AstraZeneca
Tina Nghiem Site Engagement Lead, AstraZeneca

A case study highlighting how Eli Lilly partnered with clinical sites to co-design practical, site-centric solutions that enhanced trial execution and operational efficiency.

Fireside Guest: Shafaat Ali Khan Clinical Research Lead (CRL) Director – Investigator Engagement, Eli Lilly & Co
Moderator: Jyoti Angal, PhD Director, Clinical Research, Avera McKennan Hospital & University Health Center

This case study highlights how Basil Clinical Research and Takeda’s first-time partnership became the top global recruiter, exceeding enrollment goals by tenfold through proactive assessments, early collaboration, and inclusive design. Learn how Takeda’s shift from transactional to strategic, long-term partnerships made this success possible.

• Identifying and partnering with highpotential sites
• Incorporating site feedback and early collaboration to improve trial execution
• Building trust and fostering long-term site relationships
• Key actions that led to exceptional enrollment and trial efficiency

Speakers:
Brandon Doyle, MBA Associate Director, Study Site Engagement, Takeda 
Mark Rapp, MD Principal Investigator, Basil Clinical Research

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address: 

• Integrating connectivity into drug delivery devices as a way to improve patient engagement and adherence
• How pharma can use drug delivery device data with predictive analytics to forecast demand and optimize production
• Enabling patient-centric design and innovation by analyzing device usage data

To learn more about the PODD Conference, please visit PODDConference.com.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts address how the biopharma and drug delivery industries actively move to embed sustainability into core principles, products and processes. Specifically:

• How pharma and suppliers can improve sustainability
• Creating designs with lower carbon footprints relative to fabrication and materials
• Circular recycling models

To learn more about the PODD Conference, please visit PODDConference.com.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives discuss specific examples of AI/ML usage by pharma companies through the combination product development process from iteration to commercialization as well as a discussion on how this field will evolve in the coming years.

To learn more about the PODD Conference, please visit PODDConference.com.

Manufacturing scaleup is a key hurdle in enabling the efficacy of new device technologies. Often this requires a mix of internal and external manufacturing and implementing a commercial control strategy across partners.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma and CDMO executives discuss effective partnering between pharma and manufacturing as well as growing pains and lessons learned in scaling.

To learn more about the PODD Conference, please visit PODDConference.comhttps://drug-delivery.org/.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss progess in the development of liquid/liquid and liquid/lyo dual chamber systems. Specifically, they address: 

• Overcoming primary container and autoinjector challenges for liquid-liquid delivery
• Improving upon dual chamber reconstitution devices
• Finding the right approach to navigate supply chain

To learn more about the PODD Conference, please visit PODDConference.com.

About this Podcast:
 As pharma sponsors continually assesses how to integrate AI into their ways of working, Evinova’s Chief Technology Officer, Sean Connolly, talks about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma.

Sean share his thoughts on going for low hanging fruit to encourage adoption, what he's seen in terms of pharma companies that are successfully implementing AI across their enterprise, and how he would recommend organizations that are just starting out on their AI journey assess their individual needs and priorities when it comes to AI.

More specifically, Sean discusses:  

• Separating short-term, mid-term and long-term costs and benefits of implementing AI 

• What business leaders at JP Morgan Health 2026 were saying about how they view the value of AI 

• AI deployed for bottom-line revenue versus internal team efficiency 

• What the first steps would be for sponsors to successfully integrate AI across their enterprise 

About this podcast:
Recorded at DPHARM 2025, Bayer's Dr Bernhard Glombitza reports on the development, implementation and early impact of their clinical operations reorgnization. He describes how shifting from a traditional hierarchical model to a network of highly empowered teams reduced management layers, broadening the scope of work and changed cross-country operations monitoring. 

Dr Glombitza details the results of the change thus far, including significant increases in efficiency and reduction in cost, maintaining quality levels and study targets, and improving employee job satisfaction. 

About this podcast:
In this keynote from Patients as Partners in Clinical Research 2025, Amicus Therapeutics' Chief Patient Advocate, Jayne Gershkowitz, shares how their organization established and embedded patient advocacy into their core structure for lasting impact.

More specifically, Ms Gershkowitz focuses on:

• Defining role standards and recruiting the right talent 
• Co-creatin research with patient communities and developing patient-centered outcomes
• Generating metrics that demonstrate the impact on R&D

When designing clinical trials, CMOs aim to answer meaningful questions for a plethora of stakeholders. Inherently, this results in study protocols with more measures, biomarkers and data collection that both provides a platform for strategic decision-making but also impacts patient burden, operational foot-print, timelines and cost. In this panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs address how to develop a balanced strategy that takes into account the ambition to answer these questions with the realities of complicated clinical trials.

More specifically:

• Prioritizing data collection strategy to answer key scientific questions while avoiding overcomplication
• Designing trials around real patients rather than ideal patients
• Better understanding the objectives of the study and asking the questions that achieve those objectives
• Better partnering with patients and PIs

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

Investing in developing a durable platform and strategy early leads to fewer delays throughout development. Locking requirements in early and educating teams to approach combination product development holistically lowers the time to development dramatically. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss how they used platform devices in concert with an internal engagement strategy to speed up development. Specifically, they address: 

• Advantages and disadvantages to platform approaches for device development
• Opportunities to overcome technical limitations
• Approaches to bring a platform into multiple product design history files
• Regulatory hurdles
• Assessing business case and getting organizational buy-in

To learn more about the PODD Conference, please visit Drug-Delivery.org.

About this podcast:
Recorded at the 2025 DPHARM conference, this state of the union panel convenes site, technology and pharma to discuss: 

• Different models and the pros and cons of the deployment models
• What makes a great patient matching solution
• Predicting what the future growth of this segment looks like
• The role of AI in this space

About this podcast: 
Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies. 

For more information, go to IO360summit.com.

About this podcast: 
Recorded at the 2025 CRAACO meeting, UNC Lineberger’s Comprehensive Cancer Center shares  an initiative to allow local HCPs to still provide clinical care to patients but decentralized research elements to the university system, following the FDA’s change in guidance on Form FDA 1572, which stopped requiring local healthcare professionals (HCPs) involved in DCTs to be listed if they’re only performing standard-of-care. 


Dr J Kaitlin Morrison talks about the process from an initial pilot of two sites to more than 23 today, providing cancer patients across the state the opportunity to access clinical trials. Specifically:

• How they are managing relationships with sites
• How they’re monitoring research elements
• Goals, next steps and thoughts for industry sponsors

About this podcast:
This podcast, recorded at the 2025 Patients as Partners Europe meeting, addresses how Novo Nordisk is consolidating patient insights to ensure greater knowledge-sharing, data integrity and traceability, addressing the unmet needs of patients, aligning product outcomes with patient expectations, and more. 

For more information, go to theconferenceforum.org. 

In this podcast, Kate Woda, Conference Director of the Patients as Partners in Clinical Research conference discusses what attendees can expect at the 13th annual event, including key topic areas, session highlights, presenting companies and more. For more information about the upcoming event, full agenda and speakers, visit patientsaspartnersconference.com.

In this podcast, featuring a panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs with recent M&A and partnership experience share those experiences as well as how CMOs of other small to midsize emerging biotech companies can support the conversations and operations that take place throughout the process of business development. Specifically:

• Different kinds of BD deals to be aware of
• How the CMO fits into various phases of transactions
• Appreciating how different c-suite colleagues and direct reports experience these transactions
• The different pharma teams CMOs will interact with
• What happens after the acquisition

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss conjugation and bioconjugation approaches to make ASOs and small molecules more tolerable while improving targeting. Technologies discussed include ADCs, PDCs, SMDCs, VDCs, RDCs and AOCs. Specifically they address:

• Biological and chemical challenges for these therapies
• Building out scalable manufacturing and a regulatory strategy
• Hurdles to overcome to get products to market

To learn more about the PODD Conference, please visit Drug-Delivery.org.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° about how to strategically approach hiring FTEs, insourcing, outsourcing and contracting to be appropriately prepared for the different stages of a biotech companies development from preclinical to early stage to late stage trials to commercialization. Specifically:

• Balancing the mix of hires and outsourcing
• Hiring for skillsets to enable efficiency without overhiring
• Reactive vs proactive hiring
• Building in a stage appropriate way but also hiring in time for later stages

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

While lipid nanoparticles are the most clinically advanced drug delivery system for nucleic acid therapeutics, they are only one tool in a toolbox of potential delivery vehicles.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss additional tools, including polymeric nanoparticles, protein-based nanoparticles and extracellular vesicles with a focus on:

• Where LNPs potentially fall short
• Where different tools can enable therapeutic delivery
• Challenges to achieving meaningful clinical impact for these different vehicles
• Building out a portfolio of delivery vehicles

To learn more about the PODD Conference, please visit Drug-Delivery.org.

About this podcast: 
This podcast comes from the DPHARM 2025 meeting. Pfizer details how they jointly co-designed and implemented an EDC/CDMS platform that’s fit for purpose, and analysis data set. This session focuses on:

• Engaging all stakeholders in designing the platform
• The evolution of the platform focus: the transition from the majority of data coming from EDC to 3/4 of the data from third party sources
• Impact of the advanced data analysis capabilities for risk management
• Review of impact on initial studies now using the platform 

For more information, go to DPHARMconference.com. 

About this podcast: 
Preliminary survey results conducted by the Tufts CSDD focus on the strategic and structural growth of new trial sites and partnerships in bringing trials directly to the local communities. The preliminary survey findings also shed light on the strategic and structural growth of these new trial sites and partnerships, offering valuable insights into the evolving global clinical trial landscape.

The significant shift towards bringing clinical trials directly to local communities through various innovative models is noteworthy. Many new clinical trial execution models have been introduced during the past decade including site staff embedded within clinical care settings, remote sites, retail pharmacies, urgent care facilities, and mobile units going directly into local communities. 

This session comes from the 2025 Partnerships with Sites Summit. 

About this podcast:
This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center. 

Dr Rosenberg focuses on: 

• The background and previous data of immune checkpoint blockade as monotherapy and in combination with chemotherapy, in urothelial cancer
• The potential role of Immunogenic Cell Death and whether it has a clinical impact on patient care and creating an anti-tumor immune response
• Enfortumab vedotin, an ADC targeting Nectin-4

For more information, go to IO360summit.com.

About this podcast:
This presentation from the 2025 IO360º Summit focuses on the immunological effects of radiopharmaceuticals, presented by Chaitanya Divgi, Sr Strategic Expert, Therapeutic Innovation, at Novartis. 

Specifically, this podcast dives deeper into: 

• An introduction to radioligand therapy
• A focus on PSMA-targeted radionuclide therapy
• Prelimary work on the relationship between systemic radiation therapy and immune effects at the tumor level 

For more information, visit IO360summit.com 

About this episode:
In this podcast, Dr Penny Heaton, Global Head of the Johnson and Johnson Office of the Chief Medical Officer, discusses: 

• J&J’s approach to patient centricity across the enterprise
• Her thoughts on balancing balancing safety and risk/benefit ratios with more engaged patients and more complex science
• Moving risk benefit assessments earlier into clinical development and the necessary change management
• Incorporating multiple streams of data for the purpose of creating medicines that truly address patient needs in the real world

For more information, go to PatientsasPartnersConference.com. 

In this podcast, Nicole Murphy, EVP and Head of Pharmaceutical Operations & Technology at Biogen, discusses:

• Cross-functional collaboration to deliver value
• How Biogen is using AI to enhance innovation
• Supply chain simplification
• Biogen's partnership philosophy as it relates to drug delivery
• Their recent $2 billion manufacturing investment in the Research Triangle Park
• And Biogen's acquisition of Alcyone Therapeutics 

It's an enlightening look into what real leadership in drug delivery, manufacturing and supply chain management looks like. 

For more information, go to Drug-Delivery.org.

In this podcast, Kate Woda, Conference Director of the Immuno-Oncology 360° Summit, discusses what attendees can expect at the 12th annual event, including key topic areas, session highlights, presenting companies and more.

For more information about the upcoming event, full agenda and speakers, visit IO360Summit.com.  

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with CMOs and advisory solutions firms about how CMOs can work with consultants and fractional talent to stay on budget while getting the expertise needed. Specifically:

• Different profiles of fractional consultants
• What to look for in a consultant and how to ensure alignment with the team
• Scoping the role of fractional talent and iterating as company needs evolve
• How to best work with firms representing fractional talent
• Advice for CMOs thinking about consulting

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

About this podcast:
This podcast dives deep into the fundamentals of antibody-drug conjugate design, specifically focusing on the selection of targeting antibodies, cytotoxic drugs, and linkers. Presenter Dr Deepa Pakianathan highlights key strategies for constructing ADCs and the critical differentiating features that enhance therapeutic efficacy and safety. 

For more information, go to IO360summit.com.

About this podcast:
This podcast comes from the 2025 Patients as Partners in Clinical Research conference. 

This panel discussion demonstrates how patient advocates are bridging the divide at the site level to improve patient representation in clinical trials. More specifically, this podcast focuses on: 

• Strategies for overcoming limited resources and lack of infrastructure, which can hinder inclusive clinical trial participation
• Successful models for empowering local leaders and leveraging community-based networks to increase participation
• Evaluating the impact of outreach and engagement efforts on enrollment representation and overall care equity
• And more

For more information, go to PatientsAsPartnersConference.com.

About this podcast: 
Liz Thompson, Global Development Leader, Senior Clinical Development Scientist at Roche, presented how the organization had delivered a single, cohesive protocol amendment categorization process to reduce the number of amendments and create a continuous improvement strategy, all to speed up timelines and reduce costs. This presentation comes from the September 2025 DPHARM: Disruptive Innovations to Modernize Clinical Research program. 

More specifically, Ms Thompson discusses how Roche is: 

• Leveraging historical amendment data to enable study teams to understand why protocols are being amended
• Utilizing a visual data science platform to generate insights from data to make better data-driven decisions
• Applying retrospective learning into current protocols to curb the need for amendments
• Building in business value 

For more information, go to DPHARMconference.com.

About this podcast:
This session was recorded at the September 2025 CRAACO: Clinical Research as a Care Option conference.

Rural sites represent untapped potential for reaching a broader array of patients and providing them access to life-changing clinical trials, but existing clinical trial infrastructure does not set rural sites up for success. 

Funded through the Genentech Innovation Fund, Montana State University and Billings Clinic created a rural clinical research readiness toolkit for unaffiliated rural and frontier healthcare systems to empower them to meet clinical research demands without compromising local care delivery.

More specifically, this presentation covers the tools created to toolkit empowers sites to do clinical research, including:

• Interpretable workflow templates
• A workload calculator for staff capacity planning
• Patient safety indicators to support enrollment and retention
• EHR-based visualization methods to assist clinical decision-making when trial participants are also patients
• And more

For more information, go to theconferenceforum.org.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs about how CMOs can support value creation in biotechs and how that is influenced buy the current biotech financial climate. Specifically:

• The importance of storytelling and leading thoughtfully
• Effective prioritization and execution towards the company narrative
• Balancing the team to be lean while avoiding the potential pitfalls of running lean
• Balancing the data collected to be interesting to investigators and important for the program to proceed
• Clinical data generation is better than preclinical dreams
• Strategically choosing a first indication and building sufficient scientific bridging to support subsequent indications

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

In this podcast from the DPHARM 2024 archives, Biogen discussed how they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to provide access to patients  with a clinically validated cognitive assessment who might not otherwise have the foundation to start a conversation with their physician about their cognition. 

For more information, go to DPHARMconference.com

At the March 2025 Patients as Partners conference, Merck presents how they advancing patient and community engagement through targeted initiatives designed to improve trial participation, relevance, and long-term impact. Key topics include:

• Identifying and addressing patient and community needs
• Strategies for earning trust and fostering sustained engagement
• Key collaborations and partnerships driving meaningful change
• Approaches to developing patient-centered endpoints and outcomes
• Methods for effectively communicating and disseminating trial results

For more information, go to PatientsAsPartnersConference.com

Summary: 

This session was recorded at the March 2025 Patients as Partners conference. In this session, Pfizer addressed how they were working to ensure continuity in the patient insights they were collecting, throughout the product life cycle. This included: 

• Approaches for aligning internal processes to facilitate the seamless flow of patient insights from early-phase to late-phase teams

• Suggested tools, including an AI Insights tool designed to centralize and leverage previous patient feedback, supporting a more integrated approach to patient engagement

• Strategies to build on existing insights, enhance collaboration across teams, and drive more effective patient-centered outcomes in R&D processes

For more information, go to PatientsAsPartnersConference.com.

Summary: 

From the DPHARM Archives, this podcast was recorded at the September 2024 DPHARM conference. In this podcast, BMS present how they specifically targeted the challenge of recruiting patients for clinical trials, aiming to make the process faster and easier. By bringing trials directly to patients, their ultimate objective was to significantly expedite patient enrollment. In this case example, they brought the audience through their new product model approach, for the organization's overarching goal of reducing the drug timeline from discovery to launch by three years.

About this podcast:
Recorded at the 2025 Immuno-Oncology 360º Summit, Stanford University's Dr Crystal Mackall shares work from her lab developing GD2-targeting CAR T cell therapy for the treatment of deadly pediatric brain tumor, as well as broader lessons on the evolution of cell therapy, and her forward-looking perspective on shaping the next generation of cancer treatments.

For more information, go to IO360summit.com. 

Summary:
Rescuing a clinical trial and choosing to switch vendor's mid-trial are some of the most expensive decisions biotech CMOs can make. These rescues require a significant amount of time, money and energy and may not even address the root issue behind a trial's poor performance. In this podcast, Raul Lima, SVP, Strategic Clinical Operations, inSeption Group, discusses a scaffolding approach that prioritizes areas that require immediate support without sacrificing the entirety of the trial. Specifically:

• How biotechs can better identify root causes of issues and correct them
• Mistakes CMOs make when implementing rescues
• When and how a scaffolding approach can be more resource, time and financially efficient

For more information about inSeption Group, visit inSeptionGroup.com. 

For more information about the annual Chief Medical Officer Summit 360° and its affiliated editorials, podcasts and webcasts, please visit CMO360.org.

Summary:
When developing patient-centric products for biologics, different doses, expressed by different combinations of volume/concentration may require different delivery devices. As a result, it takes a great deal of time and effort in planning and coordinating the formulation and device activities. In this podcast, Pharma and Drug Delivery executives from Nanoform, Pfizer, GSK, Takeda and Kymanox discuss how they facilitate partnerships between drug product development, device engineering and clinical study teams to determine how to balance concentration and volume and develop optimal devices for delivery and commercialization. Specifically:

• Impact on increasing concentration of drugs on deliverability
• Technical feasibility of manufacturing larger volume devices
• Patient tolerability and human factors that impact patient adherence

This panel discussion was recorded at the October 2024 PODD: Partnership Opportunities in Drug Delivery conference. For more information, go to Drug-Delivery.org.

In this podcast series, DPHARM Director Tracey Kimball with Valerie Bowling, Executive Director of the Conference Forum, break down what to expect at DPHARM 2025. Part III of this podcast series covers sessions addressing AI in Clinical Trials.